Core Viewpoint - Qianhong Pharmaceutical has reached a settlement with Jianyuan Trust to recover half of its investment in the "Chuangying 51" trust plan after a five-year dispute, highlighting the ongoing challenges faced by companies in managing trust investments and the impact of external economic conditions on asset performance [2][3][4]. Group 1: Settlement Details - On August 14, Qianhong Pharmaceutical announced it had reached a settlement with Jianyuan Trust regarding the "Chuangying 51" trust plan, resulting in a one-time payment of 56.9943 million yuan, which will be recognized as approximately 48.45 million yuan in profit for the 2025 fiscal year [2][5]. - The total investment in the two trust products purchased in 2018 amounted to 340 million yuan, with both products experiencing overdue payments [3][4]. - The settlement allows Qianhong to retain part of the trust beneficiary rights, indicating a strategy to balance risk while recovering some capital [6]. Group 2: Background of Trust Products - The "Chuangying 51" trust plan was set to mature on December 29, 2019, while the "Ruiying 64" plan was due on August 15, 2019, but both faced overdue payments due to the underlying assets' lack of liquidity and the borrower's financial difficulties [3][4]. - The total amount involved in the lawsuits against Jianyuan Trust was approximately 376.1866 million yuan, with overdue principal totaling 340 million yuan [4]. Group 3: Industry Context - The trend of companies facing challenges with trust investments is not isolated, as evidenced by other firms like Hengyin Technology and Chengdu Road and Bridge, which have also reported significant overdue amounts from trust products [7]. - The current economic environment has led to a preference for lower-risk fixed-income products among listed companies, with 36 companies reportedly investing a total of approximately 8.9 billion yuan in trust products since early 2025, reflecting a shift in investment strategy [7].

Core Viewpoint - Qianhong Pharmaceutical reached a settlement with Jianyuan Trust regarding a payment dispute from a trust plan purchased in 2018, resulting in a one-time payment of 56.9943 million yuan, which will contribute approximately 48.45 million yuan to the company's 2025 profit [1][4]. Group 1: Qianhong Pharmaceutical - Qianhong Pharmaceutical invested 170 million yuan in the "Anxin Chuangyin 51 Hao" trust plan, which was originally due on December 29, 2019 [4]. - After a prolonged legal battle lasting five years, the company agreed to withdraw its lawsuit in exchange for half of the remaining principal and earnings, amounting to 56.9943 million yuan [4]. - The expected profit increase of approximately 48.45 million yuan will be recorded in the 2025 profit statement [4]. Group 2: Jianyuan Trust - Jianyuan Trust reported a total revenue of 150 million yuan for the first half of 2025, marking an 84.89% year-on-year increase, and a net profit of 40 million yuan, up 13.36% [4][5]. - The company added 117 new trust projects in the first half of 2025, corresponding to a new trust scale of 1,080.01 billion yuan, reflecting a 785% year-on-year growth [5]. - As of June 30, 2025, Jianyuan Trust's managed trust assets reached 3,378.91 billion yuan, a 33.44% increase from the beginning of the year [5]. Group 3: Financial Performance and Business Development - In 2024, Jianyuan Trust achieved total revenue of 310 million yuan, with a net profit of 53 million yuan, representing a 25.15% year-on-year growth [7]. - The company’s solid business became a significant pillar, with interest income from proprietary business increasing by 12% to 32.5149 million yuan [7]. - Jianyuan Trust's trust asset management scale reached 2,532 billion yuan by the end of 2024, with a substantial growth of 78% from the beginning of the year [7].

Group 1 - The company held its ninth meeting of the sixth board of directors on August 13, 2025, with all nine directors present, complying with legal and regulatory requirements [2][3]. - The board approved a resolution to sign a settlement agreement with Jianyuan Trust Co., Ltd. regarding a financial product dispute, with unanimous support from all directors [2][3]. Group 2 - The settlement agreement was reached on August 13, 2025, where Jianyuan Trust paid the company a settlement amount of 56,994,275.53 yuan, which is 50% of the remaining amount after deducting previously paid principal and interest from the original investment of 170 million yuan [3][11]. - The company will submit a request to withdraw the lawsuit to the Shanghai Financial Court, and the transfer of 62,862,549.50 trust beneficiary rights to Jianyuan Trust will occur, while the company retains the remaining rights [3][11]. Group 3 - The total amount involved in the settled case was 177.8694 million yuan, with the principal amount being 170 million yuan [9][10]. - The settlement is expected to impact the company's profit by approximately 48.4451 million yuan, which will be included in the 2025 annual report [9][13].